PLA2G7 / PAFAH Antibody (Antigen Affinity Purified)

PLA2G7 / PAFAH Antibody ( Antigen Affinity Purified ) Datasheet

PLA2G7 / PAFAH Antibody Product Information

• Immunogen: Recombinant Human PLA2G7 / PAFAH protein (Catalog#10848-H08H)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Human PLA2G7 / PAFAH (rh PLA2G7 / PAFAH; Catalog#10848-H08H; Q13093-1; Met 1-Asn 441). PLA2G7 / PAFAH specific IgG was purified by Human PLA2G7 / PAFAH affinity chromatography.

PLA2G7 / PAFAH Antibody Usage Guide

• Specificity: Human PLA2G7 / PAFAH
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human PLA2G7 in WB. Using a DAB detection system, the detection limit for Human PLA2G7 is approximately 8 ng/lane under non-reducing conditions and 2 ng/lane under reducing conditions.
• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human PLA2G7. The detection limit for Human PLA2G7 is approximately 0.039 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

PLA2G7 / PAFAH Antibody Background

Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

References

1. Stafforini DM. et al., 1996, J Clin Invest. 97: 2784-91.
2. Yoshida H. et al., 1998, Thromb Haemost. 80: 372-5.
3. Yamada Y. et al., 1998, Metabolism. 47: 177-81.
4. Kruse S. et al., 2000, Am J Hum Genet. 66: 1522-30.